Adaptive Biotechnologies Invited to Present at Upcoming Conferences

SEATTLE, March 17, 2015 /PRNewswire/ -- Adaptive Biotechnologies Corporation, the pioneer in leveraging next generation sequencing to profile T-cell and B-cell receptors, today announced that members of the company's management team will present at the following upcoming 2015 conferences:

Chad Robins, Chief Executive Officer and President, will present at the Goldman Sachs Investor Conference on March 17th in New York, NY. Alongside Dr. Michael Pellini of Foundation Medicine and Eric Schadt of the Icahn Institute for Genomics, the panel will discuss how innovation can be disruptive across key sectors of the healthcare industry.

Mr. Robins will also present at the 2015 Diagnostics Industry Forum on March 19th in Washington DC. This panel, consisting of senior executives from leading laboratory diagnostics and IVD companies, will provide insight into current market conditions, recent trends and the future of the diagnostics industry. 

In April and May, Mr. Robins, along with other Seattle-based healthcare leaders, will meet to discuss personalized medicine and the booming biotech industry in the Northwest. The Personalized Medicine conference will be held on April 30^th, and the panelists include members of the WBBA, Juno Therapeutics, Nanostrong Technologies, Fred Hutchinson Cancer Research Center (FHCRC), and Ben Towne Center for Childhood Cancer. The Seattle biotech momentum will be highlighted at the Xconomy Forum on May 6^th, showcasing Adaptive, The Institute for Systems Biology, FHCRC, and The Bill & Melinda Gates Foundation. Mr. Robins will also be presenting at the Bank of America Merrill Lynch Healthcare conference on May 12^th in Las Vegas, Nevada.

Dr. Harlan Robins, Adaptive's Chief Scientific Officer, will present alongside leaders in the pharmaceutical and academic arena at the Cancer Progress Annual Conference in NYC on March 17^th. Notably, his panel includes Dr. Jedd Wolchok from Memorial Sloan Kettering who is also chairing Adaptive's new Scientific Advisory Board for Cancer Immunotherapy. Other key speakers include Axel Hoos (GlaxoSmithKline) and Nils Lonberg (Bristol Myers-Squibb). Dr. Robins and Dr. Ilan Kirsch, Adaptive's Senior Vice President of Translational Medicine, also have several upcoming talks at key medical meetings including:

• Cancer Research UK annual symposium on Friday, March 20, 2015 in Cambridge, UK
• New York Academy of Sciences Meeting on "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday, March 26, 2015 in New York, NY
• World Vaccines Conference on Tuesday April 7, 2015 in Washington, DC
• Governor's Conference on Effective Partnering in Cancer Research on Thursday, April 23, 2015 in Princeton, NJ

About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.

About immunoSEQ™
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ™ brand name. The immunoSEQ™ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ™ Assay is not for use in diagnostic procedures.

About clonoSEQ™
Adaptive uses its proprietary immunosequencing platform to validate clinical diagnostics in cancer and other immune-mediated diseases. The company's first CLIA certified clinical application, the clonoSEQ™ Assay, is used to monitor Minimal Residual Disease (MRD) in blood-based cancers. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.

The company is currently validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.

Logo - http://photos.prnewswire.com/prnh/20120103/SF28632LOGO

SOURCE Adaptive Biotechnologies Corporation